A New Drug Design Targeting the Adenosinergic System for Huntington's Disease
2011

A New Drug Design Targeting the Adenosinergic System for Huntington's Disease

Sample size: 33 publication 10 minutes Evidence: moderate

Author Information

Author(s): Huang Nai-Kuei, Lin Jung-Hsin, Lin Jiun-Tsai, Lin Chia-I, Liu Eric Minwei, Lin Chun-Jung, Chen Wan-Ping, Shen Yuh-Chiang, Chen Hui-Mei, Chen Jhih-Bin, Lai Hsing-Lin, Yang Chieh-Wen, Chiang Ming-Chang, Wu Yu-Shuo, Chang Chen, Chen Jiang-Fan, Fang Jim-Min, Lin Yun-Lian, Chern Yijuang

Primary Institution: National Research Institute of Chinese Medicine, Taipei, Taiwan

Hypothesis

Can the dual-function compound T1-11 effectively treat Huntington's disease by activating the adenosinergic system?

Conclusion

The dual functions of T1-11 enable it to effectively activate the adenosinergic system and subsequently delay the progression of Huntington's disease.

Supporting Evidence

  • T1-11 was shown to enhance motor coordination in a transgenic mouse model of Huntington's disease.
  • T1-11 reduced the formation of striatal Htt aggregates in treated mice.
  • T1-11 increased the level of brain-derived neurotrophic factor in the brains of treated mice.
  • T1-11 inhibited adenosine uptake in vivo, enhancing striatal adenosine levels.
  • T1-11 activated the A2A adenosine receptor, leading to increased cAMP levels in the brain.

Takeaway

Researchers found a new drug, T1-11, that helps mice with Huntington's disease by making their brains work better and improving their movement.

Methodology

The study involved testing T1-11 in a transgenic mouse model of Huntington's disease, assessing its effects on motor coordination, striatal Htt aggregates, and proteasome activity.

Potential Biases

Potential bias due to the use of a single animal model and the lack of human clinical trials.

Limitations

The study did not assess the long-term effects of T1-11 on survival and brain atrophy in late-stage Huntington's disease.

Participant Demographics

Transgenic mouse model of Huntington's disease (R6/2 mice).

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0020934

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication